Clinical Trial Update: REVERSE-Long COVID-19 With Baricitinib Study [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating baricitinib for post-acute COVID-19 syndrome has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute COVID-19 Syndrome

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Vanderbilt University Medical Center | Conditions: Post-Acute COVID-19 Syndrome | Phase 3 | Status: WITHDRAWN